BMW-(Turbo)-Calls mit gehebelten Renditechancen ()
BMW-(Turbo)-Calls mit gehebelten Renditechancen () | aktiencheck.de
Stay updated with breaking news from Cloud Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMW-(Turbo)-Calls mit gehebelten Renditechancen () | aktiencheck.de
Share this article Share this article ResearchAndMarkets.com's offering. Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso (duchenne muscular dystrophy, March 2020), Vyondys 53 (duchenne muscular dystrophy, December 2019) and ...